SpringWorks Therapeutics Net Income 2019-2021 | SWTX

SpringWorks Therapeutics net income from 2019 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
SpringWorks Therapeutics Annual Net Income
(Millions of US $)
2020 $-46
2019 $-51
2018 $-18
SpringWorks Therapeutics Quarterly Net Income
(Millions of US $)
2021-06-30 $-47
2021-03-31 $-30
2020-12-31 $11
2020-09-30 $-22
2020-06-30 $-20
2020-03-31 $-15
2019-12-31 $-16
2019-09-30 $-17
2019-06-30 $-14
2019-03-31 $-4
2018-12-31
2018-09-30 $-5
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.889B $0.035B
SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics Inc. is based in Stamford, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.038B 8.59
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.127B 20.54
Biohaven Pharmaceutical Holding (BHVN) United States $8.605B 0.00
Emergent Biosolutions (EBS) United States $2.673B 6.45
Arcus Biosciences (RCUS) United States $2.441B 0.00
Myovant Sciences (MYOV) United Kingdom $1.860B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.754B 0.00
Zymeworks (ZYME) Canada $1.075B 0.00
Ambrx Biopharma (AMAM) United States $0.524B 0.00
SQZ Biotechnologies (SQZ) United States $0.335B 0.00
Enzo Biochem (ENZ) United States $0.158B 15.48